<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04981366</url>
  </required_header>
  <id_info>
    <org_study_id>04234918.1.0000.0065</org_study_id>
    <nct_id>NCT04981366</nct_id>
  </id_info>
  <brief_title>Protein Supplementation in Elderly With Sarcopenic Obesity Undergoing Caloric Restriction and Exercise</brief_title>
  <official_title>Effects of the Protein Supplementation Associated With Exercise Training in Elderly With Sarcopenic Obesity Undergoing Caloric Restriction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate if protein supplementation increases the benefits of exercise&#xD;
      training in the elderly with sarcopenic obesity undergoing caloric restriction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A major subset of adults over the age of 65 is now classified as having sarcopenic obesity, a&#xD;
      high-risk geriatric syndrome predominantly observed in an aging population that is at risk of&#xD;
      synergistic complications from both sarcopenia and obesity.&#xD;
&#xD;
      Lifestyle interventions such as caloric restriction and exercise training are effective&#xD;
      nonpharmacological strategies to mitigate some adverse effects related to this condition.&#xD;
      Also, protein supplementation may boost the benefits of exercise, but this assumption is&#xD;
      still to be tested. This trial aims to test whether protein supplementation is able to&#xD;
      increase the benefits of exercise training in the elderly with sarcopenic obesity undergoing&#xD;
      caloric restriction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fat-free mass</measure>
    <time_frame>16 weeks</time_frame>
    <description>Fat-free mass evaluated trough dual-energy x-ray absorptiometry (DEXA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fat-mass</measure>
    <time_frame>16 weeks</time_frame>
    <description>Fat mass evaluated trough dual-energy x-ray absorptiometry (DEXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone mineral density</measure>
    <time_frame>16 weeks</time_frame>
    <description>bone mineral density evaluated trough dual-energy x-ray absorptiometry (DEXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone microarchitecture</measure>
    <time_frame>16 weeks</time_frame>
    <description>Bone microarchitecture will be assessed using a high resolution peripheral quantitative computed tomography (HR-pQCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function</measure>
    <time_frame>16 weeks</time_frame>
    <description>Muscle function evaluated trough battery of tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>16 weeks</time_frame>
    <description>Muscle strength will be evaluated using maximal dynamic strength test [1RM])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiorespiratory fitness</measure>
    <time_frame>16 weeks</time_frame>
    <description>Cardiorespiratory fitness will be evaluated by maximal oxygen uptake (VO²max) during a maximal exercise test on a treadmill</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity as assessed by surrogates of insulin sensitivity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Oral glucose tolerance test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lipid profile</measure>
    <time_frame>16 weeks</time_frame>
    <description>Lipid profile (i.e; HDL, LDL, VLDL, and triglycerides) will be evaluated by colorimetric enzymatic methods</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory profile</measure>
    <time_frame>16 weeks</time_frame>
    <description>Inflammatory profile (i.e.; IL1β, IL-10, IL-6, IL-4, TNF-α and C-Reactive Protein) will be quantified using the Luminex xMAP technology</description>
  </other_outcome>
  <other_outcome>
    <measure>Bone turnover</measure>
    <time_frame>16 weeks</time_frame>
    <description>Bone turnover (i.e.; CTX, P1NP, DKK1, sclerostin, osteocalcin, and osteopontin) will be quantified using the - Luminex xMAP technology;</description>
  </other_outcome>
  <other_outcome>
    <measure>Brachial flow-mediated dilation (FMD)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Brachial flow-mediated dilation (FMD) will be assessed by High-resolution B-mode ultrasound</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiometabolic Risk Score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Cardiometabolic Risk Score will be assessed by clustered cardiometabolic risk index</description>
  </other_outcome>
  <other_outcome>
    <measure>Quadriceps cross-sectional area (CSA)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Quadriceps cross-sectional area (CSA) will be assessed by computed tomography imaging</description>
  </other_outcome>
  <other_outcome>
    <measure>Muscle fiber cross-sectional area (fCSA)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Muscle fiber cross-sectional area (fCSA) will be assessed using an immunostaining assay of muscle tissue samples obtained through percutaneous muscle biopsy</description>
  </other_outcome>
  <other_outcome>
    <measure>Satellite cell content (SC) and myonuclei content</measure>
    <time_frame>16 weeks</time_frame>
    <description>Satellite cell content (SC) and myonuclei content will be assessed using an immunostaining assay of muscle tissue samples obtained through percutaneous muscle biopsy</description>
  </other_outcome>
  <other_outcome>
    <measure>Muscle fibre capillarization</measure>
    <time_frame>16 weeks</time_frame>
    <description>Muscle fibre capillarization will be assessed using an immunostaining assay of muscle tissue samples obtained through percutaneous muscle biopsy</description>
  </other_outcome>
  <other_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>16 weeks</time_frame>
    <description>Oxidative stress (i.e,; SOD, CAT, glutathione, GPx, GSH and MDA) will be determined through ELISA assay.</description>
  </other_outcome>
  <other_outcome>
    <measure>Gut hormones</measure>
    <time_frame>16 weeks</time_frame>
    <description>Gut hormones (i.e.; Ghrelin, GIP, GLP-1, PP, PYY) will be quantified using the Luminex xMAP technology</description>
  </other_outcome>
  <other_outcome>
    <measure>Telomere length</measure>
    <time_frame>16 weeks</time_frame>
    <description>Telomere length will be assessed by quantitative real-time PCR</description>
  </other_outcome>
  <other_outcome>
    <measure>Anxiety</measure>
    <time_frame>16 weeks</time_frame>
    <description>Anxiety will be assessed by the Geriatric Anxiety Inventory (GAI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Depression</measure>
    <time_frame>16 weeks</time_frame>
    <description>Depression will be assessed by the Geriatric Depression Scale (GDS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Ccognitive processing speed</measure>
    <time_frame>16 weeks</time_frame>
    <description>Cognitive processing speed will be assessed by Trail Making Test (TMT).</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive executive function</measure>
    <time_frame>16 weeks</time_frame>
    <description>Cognitive executive function will be assessed by Stroop Test (Victoria version)</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>16 weeks</time_frame>
    <description>Sleep Quality will be assessed by Pittsburgh Sleep Quality Index(TMT).</description>
  </other_outcome>
  <other_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>16 weeks</time_frame>
    <description>Health-related quality of life will be evaluated by 36-Item Short Form Health Survey questionnaire (SF-36)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Sarcopenic Obesity</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Control group (CTRL)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients allocated to this arm will not receive any intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caloric Restriction associated to exercise training plus protein supplementation (CREX+PTN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to this arm will be submitted to caloric restriction associated with exercise training program plus protein supplementation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caloric Restriction associated to exercise training plus isocaloric placebo (CREX+PLA)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients allocated to this arm will be submitted to caloric restriction associated with exercise training program plus isocaloric placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein supplement</intervention_name>
    <description>40g of whey protein in the breakfast;</description>
    <arm_group_label>Caloric Restriction associated to exercise training plus protein supplementation (CREX+PTN)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>isocaloric supplement</intervention_name>
    <description>42g of isocaloric supplement in the breakfast;</description>
    <arm_group_label>Caloric Restriction associated to exercise training plus isocaloric placebo (CREX+PLA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  65 years and older;&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 30 kg/m2;&#xD;
&#xD;
          -  Sarcopenia;&#xD;
&#xD;
          -  not engage into exercise training programas.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cancer in the last 5 years;&#xD;
&#xD;
          -  cognitive deficit or dementia that impossibility the patient to read and sign the&#xD;
             informed consent form;&#xD;
&#xD;
          -  any disease that limits participation in exercise training program.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamilton Roschel, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hamilton Roschel, Phd</last_name>
    <phone>+551130618789</phone>
    <email>hars@usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>05508-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamilton Roschel, PhD</last_name>
      <phone>+55 11 3061-8789</phone>
      <email>hars@usp.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Hamilton Augusto Roschel da Silva</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

